Zhang Guilong, Lin Yanming, Zhou Qun, Gao Liang, Zhang Leixiao, Yu Yang, Shen Yuquan, Huang Yong
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.
Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan.
Medicine (Baltimore). 2020 Jun 5;99(23):e20519. doi: 10.1097/MD.0000000000020519.
This systematic review aims to evaluate the effectiveness and safety of silver acupuncture in treatment of myofascitis.
Electronic databases of all silver acupuncture for myofascitis will be searched at PubMed, Cochrane Library, Springer, Embase, China National Knowledge Infrastructure, Wanfang, and Chinese Biological Medical disc from inception to March 31, 2020, with language restricted in Chinese and English. The primary outcome is visual analog scale, a short pain scale with sensitivity and comparability. Secondary outcomes included Clinical Assessment Scale for Cervical Spondylosis, Japanese Orthopaedic Association Scores, Oswestry dysfunction index, American Orthopaedic Foot and Ankle Society-Ankle Hindfoot scale, Foot and Ankle Ability Measure, The Cumberland ankle instability tool, Pittsburgh sleep quality index, self-rating anxiety scale, self-depression rating scale, and follow-up relapse rate. The systematic review and searches for randomized controlled trials of this therapy for myofascitis. The Cochrane RevMan V5.3 bias assessment tool is implemented to assess bias risk, data integration risk, meta-analysis risk, and subgroup analysis risk (if conditions are met). Mean difference, standard mean deviation, and binary data will be used to represent continuous results.
This study will provide a comprehensive review and evaluation of the available evidence for the treatment of myofascitis with this therapy.
This study will provide new evidence to evaluate the effectiveness and side effects of silver acupuncture for myofascitis. Due to the data are not personalized, no formal ethical approval is required.
There is no requirement of ethical approval and it will be in print or disseminated by electronic copies.
CRD42020151476.
本系统评价旨在评估银质针治疗肌筋膜炎的有效性和安全性。
检索PubMed、Cochrane图书馆、Springer、Embase、中国知网、万方和中国生物医学文献数据库中自创建至2020年3月31日所有关于银质针治疗肌筋膜炎的文献,语言限制为中文和英文。主要结局指标为视觉模拟量表,这是一种具有敏感性和可比性的简短疼痛量表。次要结局指标包括颈椎病临床评定量表、日本骨科学会评分、Oswestry功能障碍指数、美国矫形足踝协会踝后足量表、足踝能力测量量表、坎伯兰踝关节不稳工具、匹兹堡睡眠质量指数、自评焦虑量表、自评抑郁量表以及随访复发率。对该疗法治疗肌筋膜炎的随机对照试验进行系统评价和检索。采用Cochrane RevMan V5.3偏倚评估工具评估偏倚风险、数据整合风险、荟萃分析风险和亚组分析风险(如条件满足)。均值差、标准化均值差和二分类数据将用于表示连续性结果。
本研究将对该疗法治疗肌筋膜炎的现有证据进行全面综述和评价。
本研究将为评估银质针治疗肌筋膜炎的有效性和副作用提供新的证据。由于数据不涉及个人化信息,无需正式伦理批准。
无需伦理批准,将以印刷版或电子版形式传播。
PROSPERO注册号:CRD42020151476。